University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

R. Kate Kelley, M.D.

Gastrointestinal cancer specialist

Dr. R. Kate Kelley is a gastrointestinal oncologist who treats liver cancers such as hepatocellular carcinoma; bile duct cancers such as cholangiocarcinoma; gastric cancer; esophageal cancer; anal, colon and rectal cancer; pancreatic cancer; and gastrointestinal stromal tumors. In her research, her interests include developing clinical trials to identify new treatments for gastrointestinal malignancies, particularly hepatocellular carcinoma and bile duct cancers.

Kelley graduated from UCLA School of Medicine and completed a residency at UCLA, where she was chief resident in Internal medicine. She also completed a fellowship in hematology and oncology at UCSF. She received the American Society of Clinical Oncology (ASCO) Young Investigator Award in 2010 and the Gastrointestinal Cancers Symposium ASCO Foundation Merit Award in 2009. Kelley is co-author of a chapter on alimentary cancers in the textbook Current Medical Diagnosis and Treatment.

Clinics

Gastrointestinal Surgery and Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Patient Information and Appointments: (415) 353-9888
Administrative Inquiries: (415) 353-7390
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Conditions & Treatments

More about R. Kate Kelley

Additional Languages

Spanish

Education

UCLA School of Medicine 2002

Residencies

UCLA Medical Center, Internal Medicine 2005

Fellowships

UCSF Medical Center, Hematology - Oncology 2009

Selected Research and Publications

  1. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015; 15(1):206.
  2. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
  3. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
  4. Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011 Jun; 10(2):73-80.
  5. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.